|Articles|April 25, 2017
Schulman IRBs IBC Service to Launch in May
Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017.
Advertisement
Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017. The IBC service represents Schulman’s response to requests from research sponsors, CROs and institutions seeking an independent option for establishing IBCs when required by federal guidelines.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV PatientsSeptember 12th 2025
Latest NIMBLE Study Results Highlight Progress in gMG ResearchSeptember 12th 2025
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug TrialsSeptember 11th 2025
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
